RSV vaccine to prevent COPD flare-ups
Part of Lungs & breathing clinical trials.
This trial tests whether the RSV vaccine can reduce repeated COPD flare-ups. You may qualify if you are 50+, have COPD, smoke or used to smoke, and have had frequent flare-ups while on a recommended dual inhaler.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 50 years of age or older.
- You have been diagnosed with COPD based on a breathing test, and you are a current or former smoker with at least a 10 pack-year smoking history.
- You have had frequent COPD flare-ups (at least 2 moderate or 1 severe) in the past year.
- You are currently using a dual long-acting inhaler (LABA and LAMA) in one device for at least 8 weeks.
- You are up-to-date with your flu and pneumonia vaccines, received at least 1 month ago.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether RSV (a common respiratory virus) is linked to COPD flare-ups that need urgent care. By testing patients during a flare-up, researchers hope to understand how RSV affects COPD and find better ways to manage it.
This study will safely expose healthy older adults (65-75) to a mild RSV B virus to see how their immune system responds. It may help develop better vaccines or treatments for RSV in older people.
This study tests a new RSV vaccine to see if it is safe for healthy adults. It uses mRNA technology to help your body build protection against RSV, a common respiratory virus.
This trial tests a new RSV vaccine for people aged 60 and above. RSV is a common virus that can cause serious breathing problems in older adults. The study will see if the vaccine is safe and helps protect you from RSV.
This study tests an RSV vaccine in adults aged 18 and older, especially those with chronic health issues like heart or lung disease. It aims to see how safe and effective the vaccine is at preventing RSV infections.
This trial studies whether giving a booster dose of the RSV vaccine (Abrysvo) is safe and effective for adults with weakened immune systems. It includes people who have never had an RSV vaccine and those who had one or two doses in the past.
Hear when a new COPD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.